Core Insights - Climb Bio, Inc. is advancing its clinical pipeline with ongoing trials for budoprutug in immune thrombocytopenia (ITP) and systemic lupus erythematosus (SLE), and plans to initiate a trial for primary membranous nephropathy (pMN) soon [1][3][4] - The company has a strong financial position, with cash reserves expected to fund operations through 2027 [1][10] Budoprutug Program Updates - Budoprutug, an anti-CD19 monoclonal antibody, is currently in Phase 1b/2a trials for ITP and SLE, with enrollment ongoing [6][12] - The pMN Phase 2 trial is set to begin in the coming weeks, focusing on safety and preliminary efficacy [6][12] - A subcutaneous formulation of budoprutug has shown high bioavailability and favorable tolerability in non-clinical studies, with a Phase 1 trial expected to start shortly [1][6] CLYM116 Program Updates - CLYM116, an anti-APRIL monoclonal antibody, is progressing towards clinical development for IgA nephropathy (IgAN), with an IND or CTA submission anticipated in the second half of 2025 [5][14] - An investor event is planned for September 2025 to present new preclinical data on CLYM116 [1][5] Corporate Updates - Edgar D. Charles, M.D., MSc has been appointed as Chief Medical Officer, bringing over 20 years of experience in immunology-focused pharmaceutical development [8] - The company reported a net loss of $8.7 million for the second quarter of 2025, compared to a loss of $54.9 million in the same period of 2024 [10][19] Financial Highlights - As of June 30, 2025, Climb Bio had cash, cash equivalents, and marketable securities totaling $187.4 million [10][17] - Research and development expenses for the second quarter of 2025 were $6.6 million, significantly higher than $1.0 million in the same period of 2024 [10][19]
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates